FSHD Society https://validator.w3.org/feed/docs/rss2.html 2026 Walk & Roll to Cure FSHD – Live Updates & Weekly Coverage Epicrispr’s EPI-321 Trial Breaking News from Avidity Biosciences Breaking News from Avidity Biosciences How Fulcrum Therapeutics’ Phase 3 REACH Clinical Trial Will Continue to Power the Path Forward  Inside the 2025 International Research Congress on FSHD: Breakthroughs, Hope, and the Road Ahead Breaking Down Avidity’s FORTITUDE Phase 1/2 Trial Update  Opening the Door to Better Research: A New Gateway for FSHD Scientists Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy Summary of the Rare Trials Summit Advocates Secure New Avenue for Research Funding Driving Breakthroughs for FSHD Treatments Building a Clinical Data Library Avidity Biosciences Acquired by Novartis RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy Remembering Howard Chabner Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD Scholar Rock Highlights 2026 Strategic Priorities Organizations Join Forces to Map How Human Muscle Regenerates Letter to the FSHD Community from Roche Roche stops development of Emugrobart Mirecule Expands Strategic FSHD Collaboration with Sanofi Sarepta’s letter to the FSHD community The FSHD Society, SOLVE FSHD, and the FSHD CTRN Announce Launch of Industry Collaborative to Improve FSHD Clinical Trials Novartis Announces Positive Biomarker Results for Del-brax in FSHD FSHD Society Hosts First-Ever Bilingual FSHD 360 Conference in Montreal  Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321 FSHD Connect: How the Conference Brings the FSHD Community Together IRC: Reflecting on My Experience as an Industry Professional and FSHD Advocate  FSHD Industry Collaborative Expands with Four Biopharma Sponsors and Reports Rapid Advances Across Multiple Muscular Dystrophy Research Programs Novartis’ Phase 3 HARBOR Trial Results: An Update for the FSHD Community FSHD University: Pediatric Respiratory Monitoring and FSHD FDA Listening Session: Early Onset FSHD Tampa Chapter Gathering Adjunct Scientific Workshop FSHD University: Autonomy in Driving: Maintaining & Expanding Independence Scholar Rock’s FORGE Trial Media Library Indiana Chapter Virtual Meeting Indiana Chapter Virtual Meeting FSHD University: Annual Drug Development Update FSHD University: Managing FSHD Without Medication Early-onset FSHD Early Onset Patient Listening Session Summary Colorado/New Mexico Chapter Gathering Colorado/New Mexico Chapter Gathering Los Angeles Chapter In-Person Meeting Los Angeles Walk & Roll to Cure FSHD 2026 Home Blog